In this multicenter study, 30 patients undergoing matched related or unrelated allogeneic stem-cell transplantation for leukemia were treated with palifermin, and retrospectively compared to a matched control group. Palifermin recipients transplanted with an unrelated donor showed a significant reduction of severity, incidence and duration of oral mucositis WHO grades 2-4. In addition, in the palifermin group the use of opioid analgesics and the duration of total parenteral nutrition decreased, whether stem cells were used from matched related or unrelated donors. No beneficial influence of palifermin on the incidence and severity of acute GVHD (aGVHD) was apparent. The incidence and duration of febrile neutropenia, documented infections, hematopoietic recovery or overall survival remained unchanged. The most common adverse effects included rash or erythema, generally mild and transient in appearance. Thus, the administration of palifermin was generally well tolerated and safe, and significantly reduced oral mucositis whereas-regardless of donor status-no effect on the incidence and severity of aGVHD was seen.
Introduction
Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains a standard treatment for several hematological malignancies, particularly leukemia. Two major limiting toxicities associated with this procedure are acute GVHD (aGVHD) mediated by donor T-and natural killer cells and conditioning regimen-induced oral and intestinal mucositis. Depending on the conditioning regimen, oral mucositis (OM) affects up to 75% of patients who undergo HSCT 1 and is associated with significantly worse clinical and economic outcomes. 2 OM results from injury to epithelial cells and induces changes ranging from mild erythema to severe ulceration with serious clinical consequences including febrile neutropenia resulting in intensified resource use. 3 Until recently no standard therapy existed for prevention or treatment of mucositis. 4 Palifermin (Kepivance; Amgen Inc., Thousand Oaks, CA, USA) is a truncated, recombinant form of human keratinocyte growth factor (KGF) that specifically stimulates the growth of epithelial cells expressing the KGF receptor, thereby reducing chemotherapy-and radiation-induced mucosal injury. Palifermin is approved to decrease the incidence and duration of severe mucositis in patients with hematological malignancies receiving myelotoxic chemotherapy with consecutive autologous stem-cell support. 5 As gut integrity by prevention of gastrointestinal tract injury is critical in the development of subsequent aGVHD, a beneficial effect of palifermin on aGVHD has been postulated and demonstrated in animal models. 6, 7 A possible GVHD-protective effect, as indicated in these animal models could not be confirmed in a recent randomized trial including patients undergoing allo-HSCT with sibling donors. 8 However, patients with a higher aGVHD risk, such as those receiving unrelated donor grafts were not included in this trial.
This study was performed to assess the safety and efficacy profile of palifermin on OM and aGVHD in allo-HSCT, with specific attention to unrelated donor transplant recipients. Patients were between 18 and 59 years of age (median 38 years), had a diagnosis of acute or chronic leukemia (AML/ MDS (n ¼ 40), ALL (n ¼ 14), CML (n ¼ 5), CMML (n ¼ 1)) and received an allo-HSCT after myeloablative-conditioning therapy composed of either CY and TBI or chemotherapy solely. Baseline demographic-and disease characteristics are listed in Table 1 . In the palifermin group, 18 patients had an unrelated donor graft as compared to 15 in the control group.
Patients and methods

Patient characteristics
Palifermin was administered at a dose of 60 mg/kg per day for three consecutive days before the initiation of conditioning therapy and after graft infusion, as previously published. 5 Each patient of the palifermin group was assessed daily for OM according to the five-grade WHO oral-toxicity scale until mucositis had resolved. 9 As we perform daily mucositis-and GVHD assessments on a routine basis, these data were evaluated according to the five-grade WHO oral-toxicity scale in the control group. Severity of aGVHD was determined clinically and with biopsies of affected organs when appropriate, to day 100 using consensus criteria. 10 Febrile neutropenia was defined as an ANC of o0.5 Â 10 9 per liter and temperature X38.2 1C, duration of febrile neutropenia, and incidence of documented infections (clinically or microbiologically documented infection with/without bacteraemia) were defined according to Infectious Diseases Working Party of the German Society of Hematology and Oncology guidelines. 11 The safety end point of the study was the incidence of adverse events related to the study medication.
Conditioning therapy, GVHD prophylaxis and supportive care
In all but three patients the conditioning regimen consisted of CY/TBI (12-13.2 Gy fractionated TBI days -6 to -4 and CY 60 mg/kg once daily i.v. on days -3 to -2) or BU/CY (BU 1 mg/kg p.o. per dose given four times daily on days À7 to À4 and CY 60 mg/kg once daily i.v. on days À3 and À2). Prophylaxis for aGVHD consisted of CYA and MTX on days 1, 3, 6 and 11 (15 mg/m 2 i.v. on day 1, 10 mg/m 2 on days 3, 6 and 11) in addition to antithymocyte globulin (ATG) in patients receiving an unrelated or mismatched donor graft. Patients with a fully matched sibling donor received CYA with three doses of MTX (on days 1, 3 and 6) without ATG.
No growth factors were administered. Prophylaxis against fungal, viral and Pneumocystis jiroveci consisted of fluconazole, acyclovir and trimethoprime/sulfamethoxazole at most participating centers, as described. 12 Statistical analysis Statistical analysis was done using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). Differences between the experimental groups were tested by Pearson's w 2 -test, Fisher's exact test and the Mann-Whitney U-test. A two-sided P-value of 0.05 was considered to indicate statistical significance. No adjustment for multiple testing was performed.
Results
In this multicenter study patient characteristics regarding age, gender, disease and disease status at transplantation, donor status and stem-cell dose were well balanced between the two groups-with the exception of TBI-based conditioning regimens which were higher in the control group (77 vs 100%) ( Table 1) .
The incidence of OM of WHO grades 2-4 was 60% in the palifermin group and 86% in the control group (P ¼ 0.04; Table 2 ), whereas grades 3-4 was 37% in the palifermin group and 53% in the control group (P ¼ 0.19). The mean duration of OM was 6 vs 12 days (P ¼ 0.003) in favor of palifermin-treated patients. In accordance, severity of OM as exemplified by overall grading was significantly reduced in the study group (mean: 1.73 vs 2.47; P ¼ 0.03). 
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Palifermin significantly lowered the use of opioid analgesics as measured by the median cumulative dose of morphine equivalents administered (150 vs 378 mg, P ¼ 0.04), but did not impair the median time of administration (6 vs 7 days, P ¼ NS). Furthermore, the duration of total parenteral nutrition (TPN) was significantly reduced from 26 days in the control group to 15 days in the palifermin group (P ¼ 0.002). No significant difference was seen in the incidence and duration of febrile neutropenia (4 vs 3 days, P ¼ NS) or in the number of microbiologically documented infections (43 vs 40%, P ¼ NS). Hematopoietic recovery was not influenced by the administration of palifermin (Table 2) .
However, when analyzing TBI-based conditioning regimen solely (n ¼ 23 in the palifermin group, n ¼ 30 in the control group)-probably due to the smaller patient population-only secondary endpoint parameters, that is, morphine equivalents consumption, duration of TPN and duration of OM kept its statistical significance underscoring the higher mucotoxic potential of combined chemotherapy/radiotherapy-based regimens.
No significant difference was observed in the incidence of grades 2-4 (31 vs 30%, P ¼ NS) or grades 3-4 aGVHD (17 vs 20%, P ¼ NS) on day 100 after allo-HSCT. Also the distribution of organs affected by GvHD, skin, liver or gastrointestinal tract was similar (data not shown).
Overall survival rates on day 100 were similar (90 vs 86%, P ¼ NS); three patients in the palifermin group and four in the control group died before day 100. Causes of death were aGVHD/lung bleeding, CMV infection and Pseudomonas sepsis in palifermin recipients, and cerebral Toxoplasmosis, Klebsiella sepsis and two cases of venoocclusive disease in controls.
In a subgroup analysis of patients receiving unrelated donor grafts, the favorable effects of palifermin regarding incidence of severe OM grades 2-4 (44 vs 87%, P ¼ 0.01), overall mucositis grade (mean: 1.39 vs 2.60; P ¼ 0.01), administration of opioid analgesics (median, 115 mg of morphine equivalents vs 393 mg, P ¼ 0.01) and use of TPN (17 vs 28 days, P ¼ 0.02) could be maintained (Table 3) . Also, when exclusively focusing on TBI-based regimens in this subgroup analysis (n ¼ 13 in the palifermin group, n ¼ 15 in the control group), primary and secondary mucositis endpoints remained significantly different in favor of the palifermin-treated patients. However, despite the greater risk of aGVHD in unrelated donor transplantation, the use of palifermin failed to diminish the incidence and severity of aGVHD in this subgroup. Acute GVHD grades 2-4 or grades 3-4 occurred in both cohorts at identical frequencies (40 and 27%, respectively).
The administration of palifermin was generally safe. Observed adverse events including rash, erythema and taste Table 2 Results-impact of palifermin on oral mucositis and acute GVHD in allo-HSCT Table 3 Results-effect of palifermin in a subgroup analysis for allo-HSCT with unrelated donor grafts (Table 4) . Two patients discontinued the study drug after four and three single doses, respectively: the first, due to painful swelling of gum, tongue, lips and mammary glands showed an OM of grade 2; the other, because of a non-ST-segment myocardial infarction shortly after graft infusion, developed an OM of grade 1. A third patient who developed grade 3 OM failed to receive the three pretransplant doses because of a delay in drug supply.
Discussion
Similar to its effect in patients receiving autologous HSCT, 5 this study provides evidence that palifermin is able to reduce incidence, severity and duration of OM after intensive chemotherapy/radiotherapy and consecutive allo-HSCT for acute and chronic leukemia. Less mucositis resulted in less consumption of morphine equivalents and a diminished duration of TPN. These results are consistent with a randomized study with allogeneic donor transplant regimens where palifermin was associated with a reduced incidence and severity of OM in patients conditioned with the mucotoxic TBI/CY regimen but not with the somewhat less toxic BU/CY regimen. 8 A subanalysis of our study including only TBI-based conditioning regimens revealed a somewhat weaker beneficial effect of palifermin on the incidence and severity of OM, probably due to the smaller patient population but its ability to significantly influence primary and secondary mucositis endpoints in the unrelated donor transplant group was maintained. This indicates that palifermin exerts its beneficial effect predominantly in the patient population with the highest risk for developing OM. A second, retrospective study comprising a nonhomogeneous patient population undergoing autologous and allogeneic stem-cell transplantation also demonstrates the good tolerability of palifermin and its beneficial effect on OM. 13 Several rodent models have indicated that the administration of palifermin reduces the incidence and severity of aGVHD in the allo-HSCT setting. 6, 7 However, in the only randomized trial investigating a potential protective effect of palifermin against aGVHD related to allo-HSCT, no such association could be established. 8 Likewise, in the present study no association between palifermin use and incidence of aGVHD could be detected.
Nevertheless, a potential protective effect of palifermin against aGVHD may exist if a patient population with a greater aGVHD risk-that is, patients receiving unrelated donor grafts-had been included. As 18 of 30 (60%) in the palifermin group and 15 of 30 (50%) in the control group were unrelated donor transplant recipients, a subanalysis was performed confirming the beneficial results of palifermin on OM, TPN and use of opioid analgesics (Table 3) . Again, there was no significant effect of palifermin on aGVHD incidence of any grade in unrelated stem-cell transplants. A recently published retrospective trial from Poland 13 comprising a more heterogeneous patient population also reports no statistical difference in the incidence of any aGVHD. Thus, taken together, a favorable effect of palifermin on the incidence or severity of aGVHD seems very unlikely.
In conclusion, the present study demonstrated no protective effect of palifermin on aGVHD in related and unrelated stem-cell transplant recipients. Furthermore no effect on hematological recovery, day 100 survival or infectious complications was evident. Nevertheless by reducing severity, duration and incidence of OM palifermin exerts a clinically meaningful effect without adding significant toxicity and could become an integral route for preventing OM in allogeneic stem-cell transplantation regardless of whether an unrelated or related donor serves as the stem-cell source.
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